Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty liver disease (NAFLD) [1], is an emerging public health concern affecting approximately 32.4 % of people worldwide [2] and is the leading cause of chronic liver disease [3]. Individuals with MASLD exhibit a range of metabolic and hepatic conditions from a mild form of simple steatosis (SS) to severe metabolic dysfunction-associated steatohepatitis (MASH), which can progress to liver fibrosis, cirrhosis, and hepatocellular carcinoma [4–6].
